Company has become debt free for the first time since last 5 years. (Source: Standalone Financials)
Jenburkt Pharmaceuticals Share Price
Jenburkt Pharmaceutical...
Jenburkt Pharma share price insights
Company has spent less than 1% of its operating revenues towards interest expenses and 29.93% towards employee cost in the year ending Mar 31, 2024. (Source: Standalone Financials)
Stock gave a 3 year return of 125.06% as compared to Nifty Smallcap 100 which gave a return of 91.39%. (as of last trading session)
Stock generated 125.06% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)
Jenburkt Pharmaceuticals Ltd. share price moved up by 1.94% from its previous close of Rs 1,120.20. Jenburkt Pharmaceuticals Ltd. stock last traded price is 1,141.95
Share Price Value Today/Current/Last 1,141.95 Previous Day 1,120.20
Key Metrics
PE Ratio (x) | 17.98 | ||||||||||
EPS - TTM (₹) | 63.50 | ||||||||||
MCap (₹ Cr.) | 503.98 | ||||||||||
Sectoral MCap Rank | 91 | ||||||||||
PB Ratio (x) | 3.41 | ||||||||||
Div Yield (%) | 1.34 | ||||||||||
Face Value (₹) | 10.00 | ||||||||||
Beta Beta
| 1.69 | ||||||||||
VWAP (₹) | 1,119.39 | ||||||||||
52W H/L (₹) |
Jenburkt Pharma Share Price Returns
1 Day | 1.94% |
1 Week | 3.36% |
1 Month | 22.19% |
3 Months | 28.95% |
1 Year | 62.2% |
3 Years | 125.06% |
5 Years | 166.97% |
Jenburkt Pharma News & Analysis
NewsHCL Technologies among 21 stocks to trade ex-dividend on Tuesday. Last date to buy today
NewsCorporate Radar: Gujarat Themis Biosyn to go ex-dividend; Orchid Pharma board meeting and more
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
AnnouncementsCompliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Announcements
Jenburkt Pharma Share Recommendations
No Recommendations details available for this stock.
Check out other stock recos.
Jenburkt Pharma Financials
Income (P&L)
Balance Sheet
Cash Flow
Ratios
Insights
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 29.93% towards employee cost in the year ending Mar 31, 2024. (Source: Standalone Financials)
Quarterly | Annual Jun 2024 Mar 2024 Dec 2023 Sep 2023 Jun 2023 Total Income 33.94 40.03 37.01 39.38 30.21 Total Income Growth (%) -15.21 8.18 -6.04 30.36 -17.12 Total Expenses 23.77 29.61 29.09 29.78 22.71 Total Expenses Growth (%) -19.73 1.76 -2.29 31.12 -19.74 EBIT 10.18 10.42 7.91 9.61 7.50 EBIT Growth (%) -2.37 31.76 -17.67 28.05 -8.04 Profit after Tax (PAT) 7.42 7.88 5.40 7.32 5.37 PAT Growth (%) -5.91 45.85 -26.19 36.37 -15.50 EBIT Margin (%) 29.98 26.04 21.38 24.40 24.84 Net Profit Margin (%) 21.85 19.69 14.60 18.59 17.77 Basic EPS (₹) 16.80 17.86 12.25 16.59 12.17 All figures in Rs Cr, unless mentioned otherwise
Insights
All Debts Paid-off
Company has become debt free for the first time since last 5 years. (Source: Standalone Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Total Assets 165.10 141.81 142.95 120.38 104.07 Total Assets Growth (%) 16.42 -0.80 18.75 15.67 1.22 Total Liabilities 20.16 19.42 25.57 21.91 24.07 Total Liabilities Growth (%) 3.81 -24.05 16.70 -8.97 -5.09 Total Equity 144.94 122.39 117.38 98.47 80.00 Total Equity Growth (%) 18.42 4.27 19.20 23.09 3.27 Current Ratio (x) 6.70 5.14 3.57 4.46 4.52 Total Debt to Equity (x) 0.00 0.02 0.05 0.04 0.04 Contingent Liabilities 16.57 19.55 16.61 16.48 16.61 All figures in Rs Cr, unless mentioned otherwise
Insights
Cash from Operations vs PAT
Operating cash flow of Rs 8.12 cr is 0.31 times compared to the reported net profit of Rs 25.98 cr. (Source: Standalone Financials)
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Net Cash flow from Operating Activities 8.12 17.05 9.40 18.03 15.02 Net Cash used in Investing Activities -0.58 2.62 -1.33 -18.78 -2.88 Net Cash flow from Financing Activities -7.08 -21.04 -5.53 0.71 -10.83 Net Cash Flow 0.47 -1.37 2.54 -0.04 1.31 Closing Cash & Cash Equivalent 4.13 3.66 5.03 2.49 2.53 Closing Cash & Cash Equivalent Growth (%) 12.72 -27.26 101.76 -1.59 106.55 Total Debt/ CFO (x) 0.00 0.14 0.62 0.21 0.23 All figures in Rs Cr, unless mentioned otherwise
Annual FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 Return on Equity (%) 17.92 20.10 18.99 16.75 18.58 Return on Capital Employed (%) 23.83 26.36 24.90 21.58 25.70 Return on Assets (%) 15.73 17.35 15.59 13.70 14.28 Interest Coverage Ratio (x) 139.59 96.71 74.13 46.69 41.22 Asset Turnover Ratio (x) 0.93 0.96 0.94 90.79 114.24 Price to Earnings (x) 11.72 11.95 11.67 11.09 9.81 Price to Book (x) 2.10 2.40 2.22 1.86 1.82 EV/EBITDA (x) 5.96 6.83 6.73 5.38 3.82 EBITDA Margin (%) 26.61 25.95 25.97 22.09 20.15
Jenburkt Pharma Peer Comparison
Jenburkt Pharma Stock Performance
Ratio Performance
Insights
Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of 125.06% as compared to Nifty Smallcap 100 which gave a return of 91.39%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated 125.06% return as compared to Nifty Pharma which gave investors 64.02% return over 3 year time period. (as of last trading session)
Choose from Peers
Choose from Stocks
- 1D
- 1W
- 1M
- 3M
- 6M
- 1Y
- 5Y
Loading...Insights
Stock Returns vs Nifty Smallcap 100
Stock gave a 3 year return of 120.75% as compared to Nifty Smallcap 100 which gave a return of 92.43%. (as of last trading session)Stock Returns vs Nifty Pharma
Stock generated 120.75% return as compared to Nifty Pharma which gave investors 64.81% return over 3 year time period. (as of last trading session)
See All Parameters
MF Ownership
MF Ownership details are not available.
Corporate Actions
Jenburkt Pharma Board Meeting/AGM
Jenburkt Pharma Dividends
- Others
Meeting Date Announced on Purpose Details Jul 26, 2024 Jul 18, 2024 Board Meeting Quarterly Results May 28, 2024 May 21, 2024 Board Meeting Audited Results & Dividend Feb 06, 2024 Jan 19, 2024 Board Meeting Quarterly Results Nov 07, 2023 Oct 27, 2023 Board Meeting Quarterly Results Aug 08, 2023 Jul 25, 2023 Board Meeting Quarterly Results Type Dividend Dividend per Share Ex-Dividend Date Announced on Final 153% 15.3 Jul 23, 2024 May 28, 2024 Final 144% 14.4 Jul 19, 2023 May 23, 2023 Final 120% 12.0 Jul 21, 2022 May 27, 2022 Final 102% 10.2 Aug 30, 2021 Jun 02, 2021 Interim 81% 8.1 Mar 18, 2020 Mar 03, 2020 No other corporate actions details are available.
About Jenburkt Pharma
Jenburkt Pharmaceuticals Ltd., incorporated in the year 1985, is a Small Cap company (having a market cap of Rs 503.98 Crore) operating in Pharmaceuticals sector. Jenburkt Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2024. Show More
Executives
Auditors
- AU
Ashish U Bhuta
Chairman & Managing DirectorAUAshish U Bhuta
Chairman & Managing DirectorDHDilip H Bhuta
WholeTime Director & CFODHDilip H Bhuta
WholeTime Director & CFOShow More - D R Mehta & Associates
Industry
Key Indices Listed on
-
Address
Nirmala Apartments,93, Jayprakash Road,Mumbai, Maharashtra - 400058
More Details
Trending in Markets
Jenburkt Pharma Quick Links
Equity Quick Links
More from Markets
IPOStock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list
DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).
DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.
By using this site, you agree to the Terms of Service and Privacy Policy.